Home › Free Stock Grades › ADCT
ADC Therapeutics S.A. (ADCT) Stock Grade
ADCT · Healthcare
A+
Market Cap
$448.5M
P/E Ratio
—
Revenue Growth (YoY)
+14.9%
Net Margin
-175.3%
Return on Equity
76.7%
Dividend Yield
None
About ADC Therapeutics S.A.'s fundamentals
ADC Therapeutics is a biotechnology company with a market capitalization of $448.5 million that reported revenue growth of 14.9% year-over-year, indicating expanding commercial traction. However, the company carries a net margin of -175.3% and reported a net loss in its latest annual statement, reflecting ongoing cash burn typical of earlier-stage biotech firms developing novel therapies. The company does not pay a dividend and has a reported return on equity of 76.7%, though this metric's relevance is limited given the negative net income position.